August 17, 2015
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer

Onconova Announces Submission of IND for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS

TOKYO, Japan, August 13, 2015 --- SymBio Pharmaceuticals limited (Headquarters: Tokyo, "SymBio") announced today that its U.S. partner, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova") has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for IV rigosertib in the treatment of higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agent (HMA) therapy. Upon IND clearance, Onconova plans to initiate a global, randomized controlled Phase 3 pivotal trial in patients with this HR-MDS indication. According to the President and CEO of Onconova, Ramesh Kumar, Ph.D., the company expects to initiate patient enrollment for the new study in the 2H of 2015.

After completion of its ongoing Phase 1 trial in Japan for IV rigosertib (SyB L-1101) in the treatment of relapsed or refractory HR-MDS patients, SymBio plans to participate in Onconova's global Phase 3 pivotal trial.

For more details in this press release, please visit Onconova's homepage at
http://investor.onconova.com/releases.cfm

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125